Trial Profile
A study assessing gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2020
Price :
$35
*
At a glance
- Drugs Gimsilumab (Primary)
- Indications COVID 2019 infections; Respiratory distress syndrome
- Focus Adverse reactions
- Sponsors Roivant Sciences
- 27 Mar 2020 Status changed from active, no longer recruiting to completed, according to a Altasciences Company Inc medi release.
- 26 Mar 2020 Status changed from planning to active, no longer recruiting, based on the Roivant sciences media release.
- 26 Mar 2020 New trial record